Forward PE Ratio: N/A
The forward PE ratio is N/A as of Thursday, July 9, 2026.
Forward PE Ratio (N/A) = Close Price ($9.21) / Consensus Forward EPS ($-0.91)
TDOC Forward PE Ratio Metrics
FORWARD PE RATIO
N/A
TDOC Competitors' Forward PE Ratio
Teladoc Health, Inc.
Market Cap
$1.66B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Teladoc Health, Inc. (TDOC) | $1.66B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.38B | 8.31 |
| TransMedics Group, Inc. (TMDX)vs › | $2.49B | 36.64 |
| National Research Corporation (NRC)vs › | $489.27M | 24.85 |
| Shoulder Innovations, Inc. (SI)vs › | $440.27M | N/A |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.04B | 31.40 |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | 29.55 |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 15.56 |
Trailing vs Forward
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $9.21 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.91 | $-1.05 – $-0.79 | 10 | n/m |
| 2027-12-31 | $-0.64 | $-0.98 – $-0.48 | 10 | n/m |
| 2028-12-31 | $-0.54 | $-1.08 – $0.29 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Related Metrics
About Teladoc Health, Inc.
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Charles Divita